PREDICtors for Quality of Life After Sigmoidectomy for DIVerticular Disease (PREDIC-DIV)

Städtisches Klinikum München GmbH

Status: Enrolling

Conditions: Quality of Life; Diverticular Disease of Colon

Study type: Observational

Funder types: Other

Identifiers

NCT03527706

PREDIC-DIV 1.0

Details and patient eligibility

About

To identify predictors for postoperative health related quality of life after elective sigmoidectomy for diverticular disease.

Full description

According to current international guidelines, indications for surgical treatment of diverticular disease are inhomogeneous. To date, the measurement of pre- and postoperative quality of life (QoL) is underrepresented. To ensure an individually tailored therapeutical approach, and to avoid unnecessary surgery as well as the risk of a hazardous chronification of the disease, QoL importantly needs to be focused within the decisional process for the best treatment option. The aim of the PREDIC DIV-Study is, to identify predictors for a better postoperative quality of life in patients who undergo elective sigmoidectomy for diverticular disease. PREDIC DIV is a prospective observational study.

Enrollment: 165 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients, scheduled for elective sigmoidectomy for diverticular disease (Indication: foregoing acute diverticulitis with pericolic or pelvic abscess >1cm, ongoing complaints after acute uncomplicated diverticulitis, recurrent uncomplicated disease (three or more diverticulitis episodes in combination with the patients wish for surgery), recurrent complicated disease (three or more diverticulitis episodes+complications: stenosis, fistula, chronic pain), urgent wish of patients for surgery after uncomplicated disease.
• Age >18 years
• ASA 1-3
• informed consent

Exclusion criteria

• Age <18 years
• ASA 4
• acute diverticulitis with free perforation
• acute or forgoing diverticular bleeding
• colorectal malignancies (current or foregoing)
• immunosuppression (corticoids > 20 mg prednisolon/d, status post transplant)
• advanced malignancy with systemic metastases